DE69534946D1 - Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren - Google Patents

Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren

Info

Publication number
DE69534946D1
DE69534946D1 DE69534946T DE69534946T DE69534946D1 DE 69534946 D1 DE69534946 D1 DE 69534946D1 DE 69534946 T DE69534946 T DE 69534946T DE 69534946 T DE69534946 T DE 69534946T DE 69534946 D1 DE69534946 D1 DE 69534946D1
Authority
DE
Germany
Prior art keywords
antigen
host
tumor
tumors
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69534946T
Other languages
English (en)
Other versions
DE69534946T2 (de
Inventor
A Carson
Eyal Raz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23306377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69534946(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of DE69534946D1 publication Critical patent/DE69534946D1/de
Application granted granted Critical
Publication of DE69534946T2 publication Critical patent/DE69534946T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
DE69534946T 1994-11-03 1995-11-01 Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren Revoked DE69534946T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US334260 1989-04-10
US08/334,260 US5679647A (en) 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
PCT/US1995/014097 WO1996014074A1 (en) 1994-11-03 1995-11-01 Methods and devices for immunizing a host to tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides

Publications (2)

Publication Number Publication Date
DE69534946D1 true DE69534946D1 (de) 2006-05-24
DE69534946T2 DE69534946T2 (de) 2006-12-28

Family

ID=23306377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534946T Revoked DE69534946T2 (de) 1994-11-03 1995-11-01 Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren

Country Status (8)

Country Link
US (1) US5679647A (de)
EP (1) EP0789574B1 (de)
JP (1) JPH10509702A (de)
AT (1) ATE323496T1 (de)
AU (1) AU4198196A (de)
CA (1) CA2203991C (de)
DE (1) DE69534946T2 (de)
WO (1) WO1996014074A1 (de)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US20020164318A1 (en) * 1997-02-18 2002-11-07 Houghton Alan N. Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
AU8444698A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into multicelled eukaryo tic organism cells and combination therefor
ATE275423T1 (de) 1997-06-30 2004-09-15 Aventis Pharma Sa Verabreichung der nukleinsäure in den quergestreiften muskel
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
DE69840524D1 (de) * 1997-08-13 2009-03-19 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
JP2002517179A (ja) 1997-11-28 2002-06-18 ジェンセット Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
WO1999031115A1 (en) 1997-12-16 1999-06-24 The University Of Saskatchewan Conductive metal-containing nucleic acids
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
ATE247979T1 (de) * 1998-02-25 2003-09-15 Us Gov Sec Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort
EP1356823B1 (de) * 1998-02-25 2013-01-02 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der durch ein Adjuvant induzierten Immunantwort
EP1849477A1 (de) * 1998-02-25 2007-10-31 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Mitteln zur Verbesserung der Hautpenetration und schrankenbrechenden Mitteln zur Verbesserung der transkutanen Immunantwort
CA2323232A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for antigen-specific vaccination
TR200002938T2 (tr) 1998-04-07 2001-02-21 Corixa Corporation Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı
CA2331846C (en) 1998-05-13 2010-01-12 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
BR9910643A (pt) 1998-05-22 2001-10-30 Loeb Health Res Inst At The Ot Processos e produtos para a indução de imunidadede mucosa
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
CA2344972A1 (en) 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
US7160869B2 (en) * 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
EP1165132B1 (de) 1999-04-08 2011-10-19 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
KR20080098695A (ko) * 1999-05-03 2008-11-11 더 유에이비 리서치 파운데이션 비-침입성 유전자 면역, 이로부터의 발현 산물, 및 이의 용도
MXPA01011250A (es) * 1999-05-06 2002-08-12 Univ Wake Forest Composiciones y metodos para identificar antigenos que producen una respuesta inmune.
US20020151515A1 (en) * 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
WO2001000663A2 (en) * 1999-06-28 2001-01-04 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US7015204B1 (en) * 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
ATE445643T1 (de) 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
EP1842549A3 (de) 1999-12-28 2007-10-17 Pharmexa Inc. Optimierte Minigene und mit diesen kodierte Peptide
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1259265B1 (de) * 2000-03-03 2011-06-01 Genetronics, Inc. Nukleinsäure-fomulierungen zur genverabreichung
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
EP2248910A1 (de) * 2000-04-28 2010-11-10 Mannkind Corporation Epitope-Synchronisierung in Antigen presentierenden Zellen
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2001082964A1 (en) * 2000-04-28 2001-11-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
DE60124899T2 (de) * 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6595947B1 (en) * 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
PT1296714E (pt) 2000-06-22 2009-10-15 Coley Pharm Gmbh Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro
ES2323407T3 (es) 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
WO2002018578A2 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
AU2002239410B2 (en) * 2000-10-31 2008-05-01 Eisai Inc. CYP1B1 nucleic acids and methods of use
US7393921B2 (en) * 2000-12-04 2008-07-01 Institute For Systems Biology Prostate-specific polypeptide pamp and encoding nucleic acid molecules
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP1560919A2 (de) * 2001-03-29 2005-08-10 Genetic Technologies, L.P. Verbesserte hybridgenbibliotheken und deren verwendungen
JP2004527524A (ja) * 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2447089A1 (en) * 2001-05-24 2002-11-28 University Of Saskatchewan Technologies Inc. Nucleic acid circuit elements and methods
JP2004532698A (ja) * 2001-06-08 2004-10-28 ベクトン・ディキンソン・アンド・カンパニー ニードルまたはアブレーダーアレイの操作のための装置
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE420654T1 (de) 2001-08-15 2009-01-15 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
EP1439870B1 (de) * 2001-10-29 2009-01-14 Becton, Dickinson and Company Vorrichtung für die abgabe einer substanz
WO2003063770A2 (en) * 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
US20060110790A1 (en) * 2002-05-06 2006-05-25 Robert Molday Expression system for large functional proteins
CA2385110A1 (en) * 2002-05-06 2003-11-06 University Of British Columbia Co-expression system for large functional proteins
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US7422567B2 (en) * 2002-08-29 2008-09-09 Becton, Dickinson And Company Microabrader with controlled abrasion features
JP2006503914A (ja) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1594892A2 (de) 2003-02-10 2005-11-16 Agensys, Inc. Nukleinsäure und entsprechendes protein mit der bezeichnung 158p1d7, das sich für die behandlung und den nachweis von blasenkrebs und anderen krebserkrankungen eignet
US20040235019A1 (en) * 2003-03-06 2004-11-25 Agouron Pharmaceuticals, Inc. Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
WO2004098497A2 (en) * 2003-04-28 2004-11-18 Genencor International, Inc. Cd4+ human papillomavirus (hpv) epitopes
PL1629088T3 (pl) 2003-05-30 2012-06-29 Agensys Inc Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
AU2004268616B2 (en) 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
CA2536735C (en) * 2003-09-05 2013-01-22 Genencor International, Inc. Methods for determining cd8+ t-cell epitopes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
MXPA06013168A (es) * 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
CA2567449C (en) 2004-05-28 2014-03-11 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7316665B2 (en) 2004-08-25 2008-01-08 Becton, Dickinson And Company Method and device for the delivery of a substance including a covering
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2351577A1 (de) * 2004-12-29 2011-08-03 Mannkind Corporation Verfahren zum Auslösen, Beibehalten und Manipulieren von Immunantworten durch gezielte Verabreichung von Modifikationsmitteln der biologischen Reaktion in lymphatische Organe
AU2005321904B2 (en) * 2004-12-29 2012-07-12 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
CA2597404A1 (en) * 2005-02-11 2006-08-17 Merck & Co. Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
KR20070120970A (ko) * 2005-02-23 2007-12-26 유에이비 리서치 파운데이션 알킬-글리코시드로 증진된 예방접종
EP2325306B1 (de) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptid-Impfstoff für Lungenkrebs, der TTK, URLC10 oder kOC1 polypeptide exprimiert
SI2095822T1 (sl) 2005-02-28 2013-12-31 Oncotherapy Science, Inc. Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide
KR20070110901A (ko) 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
CN101278196B (zh) 2005-07-27 2013-05-15 肿瘤疗法科学股份有限公司 结肠癌相关基因tom34
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
EP1948139A4 (de) * 2005-11-18 2012-04-04 3M Innovative Properties Co Überziehbare zusammensetzungen, daraus erhaltene überzüge und mikroanordnungen mit diesen überzügen
WO2007075614A1 (en) * 2005-12-21 2007-07-05 3M Innovative Properties Company Microneedle devices
SG175566A1 (en) 2006-10-17 2011-11-28 Oncotherapy Science Inc Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
AU2008226337B2 (en) * 2007-03-14 2012-02-16 BioLingus IP II GmbH Method for treating cancer via the mucosal administration of interleukin
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
EP3085707B1 (de) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr-bindende peptide und deren anwendungen
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
DK2853269T3 (da) 2008-05-19 2019-08-05 Advaxis Inc Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
JP2012506858A (ja) * 2008-10-23 2012-03-22 インターベット インターナショナル ベー． フェー． Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓワクチン
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP3115063A3 (de) 2008-12-03 2017-04-19 The John Hopkins University Galektin-3 und annexin a2 als immunologisches zielmolekül
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
EP2387609B1 (de) 2009-01-13 2018-05-16 Stembios Technologies, Inc. Nichtembryonische stammzellen und ihre verwendung
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
SG2014013148A (en) 2009-03-18 2014-07-30 Oncotherapy Science Inc Neil3 peptides and vaccines including the same
CA2760042C (en) 2009-04-27 2020-03-10 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
CN103097519B (zh) 2010-08-04 2016-08-03 干细胞生物科技公司 体干细胞
CA2809360A1 (en) 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
WO2012071513A2 (en) 2010-11-24 2012-05-31 Hong Gao Expanding hematopoietic stem cells
JP6228010B2 (ja) 2010-12-27 2017-11-08 ブラウン ユニバーシティ ビグリカンおよびユートロフィンに関する治療法および診断法
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
ES2645156T3 (es) 2011-03-21 2017-12-04 Altimmune Inc. Agente terapéutico inmunológico de acción rápida y prolongada
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
ES2613808T3 (es) 2011-07-29 2017-05-26 Oncotherapy Science, Inc. Péptido derivado de ERAP1 y uso del mismo
WO2013024582A1 (en) 2011-08-12 2013-02-21 Oncotherapy Science, Inc. Mphosph1 peptides and vaccines including the same
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
KR20140062139A (ko) 2011-09-16 2014-05-22 페이트 세러퓨틱스, 인코포레이티드 Ｗnt 조성물 및 당해 조성물의 치료학적 용도
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
KR102020491B1 (ko) 2011-10-28 2019-09-10 온코세라피 사이언스 가부시키가이샤 Ｔｏｐｋ 펩티드 및 이를 포함하는 백신
CN103239734B (zh) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
JP2015511602A (ja) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド リステリアワクチン処理後のサプレッサー細胞機能抑制
US9561265B2 (en) 2012-07-10 2017-02-07 Oncotherapy Science, Inc. KIF20A epitope peptides for TH1 cells and vaccines containing the same
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
CN107881158B (zh) 2012-09-11 2021-11-16 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
PL2931304T3 (pl) 2012-12-13 2021-11-08 The Trustees Of The University Of Pennsylvania Szczepionka wt1
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP2978450B1 (de) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Verfahren zur erhöhung der wirksamkeit eines survivin-impfstoffs zur behandlung von krebs
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2014194244A1 (en) 2013-05-30 2014-12-04 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
DK3054972T3 (da) 2013-10-07 2019-06-11 Univ Pennsylvania Vacciner med interleukin-33 som et adjuvans
WO2015070027A1 (en) 2013-11-07 2015-05-14 University Of Southern California Use of ikk epsilon inhibitors to activate nfat and t cell response
CA3233605A1 (en) 2013-11-14 2015-05-21 The Trustees Of The University Of Pennsylvania Hiv-1 env dna vaccine plus protein boost
US10016497B2 (en) 2013-11-29 2018-07-10 The Trustees Of The Universtiy Of Pennsylvania MERS-CoV vaccine
CA3156357A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
CA2956132A1 (en) 2014-08-04 2016-02-11 Oncotherapy Science, Inc. Cdca1-derived peptide and vaccine containing same
CN106715461B (zh) 2014-08-04 2020-11-24 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
US10576097B2 (en) 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
JP6737778B2 (ja) 2014-10-01 2020-08-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２１を有するワクチン
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2963602A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
ES2811367T3 (es) 2014-11-17 2021-03-11 Cellectar Biosciences Inc Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer
CA2972635A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
ES2929532T3 (es) 2015-01-29 2022-11-30 Univ Pennsylvania Combinaciones de inhibidores de puntos de control y vacunas y su uso en inmunoterapia
AU2016229238B2 (en) 2015-03-06 2022-06-02 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
WO2016183420A1 (en) 2015-05-13 2016-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR20180056778A (ko) 2015-10-08 2018-05-29 온코세라피 사이언스 가부시키가이샤 Foxm1 유래 펩티드 및 이를 포함하는 백신
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
CN109152818B (zh) 2015-12-21 2023-06-23 杜克大学 具有降低的抗原性的聚合物结合物及其使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017165412A2 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
KR102624967B1 (ko) 2016-04-29 2024-01-16 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
EP3515559A4 (de) 2016-09-20 2020-07-15 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifizierung, beurteilung, prävention und behandlung von aml mit usp10-biomarkern und modulatoren
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
US20190358238A1 (en) 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
US10376495B2 (en) 2016-11-23 2019-08-13 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
WO2018129040A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US10813935B2 (en) 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer
US10272052B2 (en) 2017-02-24 2019-04-30 University Of South Florida Compositions and methods for the treatment of tauopathies
US11318155B2 (en) 2017-02-24 2022-05-03 University Of South Florida Hsp90 activator Aha1 drives production of pathological tau aggregates
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
US11980671B2 (en) 2017-07-26 2024-05-14 Duke University Use of bacterial voltage gated ion channels for human therapies
US11306059B2 (en) 2017-10-25 2022-04-19 University Of South Florida Drug-induced activation of the Reelin signaling system
US10538553B2 (en) 2018-01-05 2020-01-21 University Of South Florida Compounds for the treatment of neurodegenerative diseases
WO2019144047A1 (en) 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
US11491206B1 (en) 2018-02-13 2022-11-08 Duke University Compositions and methods for the treatment of trail-resistant cancer
US20200407700A1 (en) 2018-02-26 2020-12-31 President And Fellows Of Harvard College Compositions of parp14 modulators and/or mutants and therapeutic use thereof
WO2019199673A1 (en) 2018-04-09 2019-10-17 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
JPWO2020111167A1 (ja) 2018-11-30 2021-10-28 国立大学法人徳島大学 Ｂｉｇ３−ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬
EP3962529A4 (de) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
MX2022010460A (es) 2020-02-25 2022-09-19 Inovio Pharmaceuticals Inc Vacunas contra el coronavirus y metodos de uso.
KR20230011335A (ko) 2020-05-14 2023-01-20 이노비오 파마수티컬즈, 인크. 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법
CA3181680A1 (en) 2020-06-12 2021-12-16 University Of Rochester Encoding and expression of ace-trnas
EP4229222A2 (de) 2020-10-19 2023-08-23 Dana-Farber Cancer Institute, Inc. Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
WO2022178438A1 (en) 2021-02-22 2022-08-25 Duke University Non-immunogenic poegma-aptamer conjugates
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4373528A2 (de) 2021-07-19 2024-05-29 New York University Adeno-assoziierte virale vektorzusammensetzungen und verfahren zur förderung der muskelregeneration
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2024011033A1 (en) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogens and methods for inducing an immune response
WO2024102187A1 (en) 2022-11-07 2024-05-16 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery

Also Published As

Publication number Publication date
US5679647A (en) 1997-10-21
CA2203991A1 (en) 1996-05-17
JPH10509702A (ja) 1998-09-22
EP0789574B1 (de) 2006-04-19
ATE323496T1 (de) 2006-05-15
WO1996014074A1 (en) 1996-05-17
EP0789574A1 (de) 1997-08-20
AU4198196A (en) 1996-05-31
CA2203991C (en) 2002-08-20
EP0789574A4 (de) 2001-08-29
DE69534946T2 (de) 2006-12-28

Similar Documents

Publication Publication Date Title
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
US6338853B1 (en) Anti-cancer vaccine
DE19602985A1 (de) Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1961819A3 (de) Zusammensetzungen und Verfahren zur Heilung und Diagnose von Lungenkrebs
US5993829A (en) Anti-cancer vaccine
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
Inomata et al. Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG).
Cohen et al. Some biological factors increasing the radiosensitivity of an isogenic mammary tumour in C3H mice
WO2001098339A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation